REGENXBIO to Showcase Groundbreaking Surabgene Lomparvovec in Upcoming Investor Event for Wet AMD Treatment#United_States#New_York#Wet_AMD#REGENXBIO#Surabgene_Lomparvovec
REGENXBIO to Showcase Groundbreaking Surabgene Lomparvovec in Upcoming Investor Event for Wet AMD Treatment
Mark your calendars! REGENXBIO will present key insights on surabgene lomparvovec during an investor event on October 20, 2026, shedding light on its pivotal trials.
third-news.com
October 12, 2026 at 11:08 AM
REGENXBIO to Showcase Groundbreaking Surabgene Lomparvovec in Upcoming Investor Event for Wet AMD Treatment#United_States#New_York#Wet_AMD#REGENXBIO#Surabgene_Lomparvovec
Anticipated Growth in Wet AMD Market Driven by New Therapies and Aging Population#None#Wet_AMD#REGENXBIO#Adverum_Biotechnologies
Anticipated Growth in Wet AMD Market Driven by New Therapies and Aging Population
The Wet AMD market is poised for significant growth by 2036, fueled by advancements in treatments and a rising aging demographic. Key emerging therapies are set to transform care.
third-news.com
May 27, 2026 at 12:48 PM
Anticipated Growth in Wet AMD Market Driven by New Therapies and Aging Population#None#Wet_AMD#REGENXBIO#Adverum_Biotechnologies
Global Age Related Macular Degeneration Market Expected to Surpass $16.2 Billion by 2033#None#Wet_AMD#Aflibercept#Age_Related_Macular_Degeneration
Global Age Related Macular Degeneration Market Expected to Surpass $16.2 Billion by 2033
The global age-related macular degeneration market is projected to reach $16.2 billion by 2033, driven by rising cases and aging populations.
third-news.com
February 25, 2026 at 4:43 PM
Global Age Related Macular Degeneration Market Expected to Surpass $16.2 Billion by 2033#None#Wet_AMD#Aflibercept#Age_Related_Macular_Degeneration
REGENXBIO Completes Enrollment in Landmark Trials for Vision Loss Treatment#United_States#Wet_AMD#Rockville#REGENXBIO#surabgene
REGENXBIO Completes Enrollment in Landmark Trials for Vision Loss Treatment
REGENXBIO Inc. has wrapped up participant enrollment in pivotal studies for its gene therapy aimed at treating wet AMD. This marks a significant step in fighting vision loss globally.
third-news.com
October 6, 2025 at 11:17 AM
REGENXBIO Completes Enrollment in Landmark Trials for Vision Loss Treatment#United_States#Wet_AMD#Rockville#REGENXBIO#surabgene
Avirmax Biopharma Reaches Key Milestone with ABI-110 Clinical Trial Enrollment Completion#USA#Avirmax_Biopharma#Wet_AMD#ABI-110#Hayward
Avirmax Biopharma Reaches Key Milestone with ABI-110 Clinical Trial Enrollment Completion
Avirmax Biopharma has successfully completed the first cohort of patient enrollment for its ABI-110 clinical trial targeting Wet AMD and PCV, marking a significant milestone.
third-news.com
February 3, 2025 at 1:12 PM
Avirmax Biopharma Reaches Key Milestone with ABI-110 Clinical Trial Enrollment Completion#USA#Avirmax_Biopharma#Wet_AMD#ABI-110#Hayward
Avirmax Biopharma Launches Groundbreaking Gene Therapy Trial for Wet AMD#USA#Avirmax_Biopharma#Wet_AMD#ABI-110#Hayward
Avirmax Biopharma Launches Groundbreaking Gene Therapy Trial for Wet AMD
Avirmax Biopharma has commenced the Phase I/IIa trial of ABI-110, a pioneering gene therapy targeting Wet Age-related Macular Degeneration and PCV.
third-news.com
November 22, 2024 at 11:15 AM
Avirmax Biopharma Launches Groundbreaking Gene Therapy Trial for Wet AMD#USA#Avirmax_Biopharma#Wet_AMD#ABI-110#Hayward